publisher, city and/or country where published.

PTO/SB/05e (08-08)
Approved for use through 08/30/2008 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		10550165
	Filing Date		2006-07-21
	First Named Inventor	Paul:	Savage
	Art Unit		1623
	Examiner Name	Gana	pathy Krishnan
	Attorney Docket Number		017968-9010-LIS00

					U.S.I	PATENTS			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Patentee or Applicant Re		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wisi	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add		_	
U.S.PATENT APPLICATION PUBLICATIONS Remove												
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion		faited Decument		ages,Columns,Lines where elevant Passages or Relevant gures Appear			
	1											
If you wish to add additional U.S. Published Application citation information please click the Add button. Add												
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	where Re	or Relevant	Ta	
1 2003/018039 WO			2003-03-06	DNA Informatics Inc.								
If you wis	h to a	l dd additional Foreign Pa	atent Do	cument	citation	information p	lease click the Add	button	Add		_	
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove	•	_	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),									Тя			

	1		TKIEWICZ, R.R. et al., "CD1d-mediated antigen presentation to na unology (2003) 23.403-419	tural killer T (NKT) cel	ls," Critical Reviews in				
	2		BRUTKIEWICZ, R.R et al., "Natural Killer T (NKT) Cells and Their Role in Antitumor Immunity," Critical Reviews in Oncology/Hematology (2002) 41:287-298						
	3 SINGH, A.K. et al., "The Natural Killer T Cell Ligand Alpha-Galactiosylceramide Protects More Against EAE by an IL-4- and IL-10- Dependent Mechanism", FASEB J., Fed. of Amer. Soc. for Exp. Bio. (2002) 16:A1043								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Signa	ture	Examiner Signature Date Considered						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1se kind Code of USPTO Petert Documents at InverUSETO.000/ or MPEP 901.04. 2 Enter office that issued the document, by the Involved country, the Involved Code (WPD Standard ST.3). 2 The Lapteace patient counters, the includation of the year of the register to interpreted the sental runber of the patient or the patient of the Counters of the Code (WPD Standard ST.3). 2 The Lapteace patient counters of the Standard ST.3 (ST.9) and ST.3 (ST.9) and ST.3 (ST.9) are considered ST.3